Virologic testing in the management of perinatal HIV exposure

AIDS Reader

Volumn 13, Issue 1, 2003, Pages 39-46

  Cervia, Joseph ^a   Kaplan, Blanka ^b   Schuval, Susan ^b   Weiss, Susan ^b  

^a LONG ISLAND JEWISH MEDICAL CENTER   (United States)

^b NONE

Author keywords

Antiretroviral therapy; HIV AIDS; Perinatal; Transmission

Indexed keywords

ANTIRETROVIRUS AGENT; ANTIVIRUS AGENT; CD4 ANTIGEN; PLACEBO; VIRUS DNA; VIRUS RNA; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LABORATORY TEST; MAJOR CLINICAL STUDY; META ANALYSIS; MULTICENTER STUDY; NONHUMAN; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK FACTOR; VERTICAL TRANSMISSION; VIRUS DETECTION; VIRUS INFECTION; VIRUS LOAD; VIRUS TRANSMISSION;

DEVELOPING COUNTRIES; DISEASE PROGRESSION; DISEASE TRANSMISSION, VERTICAL; DRUG MONITORING; HIV INFECTIONS; HIV-1; HUMANS; INFANT, NEWBORN; NEEDS ASSESSMENT; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RESEARCH; RNA, VIRAL; VIRAL LOAD;

EID: 0037247916     PISSN: 10530894     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Bartlett JG, Gallant JE. Medical Management of HIV Infection, 2001-2002. Baltimore: Johns Hopkins University Division of Infectious Disease; 2001:10-14.
2. Kuhn L, Steketee RW, Abrams EJ, et al. Distinct risk factors for intrauterine and intrapartum human immunodeficiency virus transmission and consequences for disease progression in infected children. J Infect Dis. 1998;179:52-58.
3. John GC, Nduati RW, Mbori-Ngacha DA, et al. Correlates of mother-to-child human immunodeficiency virus type 1 (HIV-1) transmission association with maternal plasma HIV-1 RNA load, genital HIV-1 DNA shedding, and breast infections. J Infect Dis. 2001;183:206-212.
4. Kourtis AP, Bulterys M, Nesheim SR, et al. Understanding the timing of HIV transmission from mother to infant. JAMA. 2001;285:709-712.
5. Landesman SH, Kalish LA, Burns DN, et al. Obstetrical factors and the transmission of human immunodeficiency virus type 1 from mother to child. N Engl J Med. 1996;334:1617-1623.
6. Garcia PM, Kalish LA, Pitt J, et al. Maternal levels of plasma human immunodeficiency virus type 1 RNA and the risk of perinatal transmission. N Engl J Med. 1999;341:394-402.
7. Dunn DT, Simonds RJ, Bulterys M, et al. Interventions to prevent vertical transmission of HIV-1: effect on viral detection rate in early infant samples. AIDS. 2000;14:1421-1428.
8. Phuapradit W, Panburana P, Jaovisidha A, et al. Maternal viral load and vertical transmission of HIV-1 in mid-trimester gestation. AIDS. 1999;13:1927-1931.
9. Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N Engl J Med. 1994;331:1173-1180.
10. Shih CC, Kaneshima H, Rabin L, et al. Postexposure prophylaxis with zidovudine suppresses human immunodeficiency virus type 1 infection in SCID-hu mice in a time-dependent manner. J Infect Dis. 1991;163:625-627.
11. Ruprecht RM, O'Brien LG, Rossoni LD, Nusinoff-Lehrman S. Suppression of mouse viraemia and retroviral disease by 3′-azido-3′-deoxythymidine. Nature. 1986;323:467-469.
12. Sharpe AH, Jaenisch R, Ruprecht RM. Retro-viruses and mouse embryos: a rapid model for neurovirulence and transplacental antiretroviral therapy Science. 1987;236:1671-1674.
13. Shapiro DE, Sperling RS, Coombs RW. Effect of zidovudine on perinatal HIV-1 transmission and maternal viral load. Lancet. 1999;354:156-158.
14. Sperling RS, Shapiro DE, Coombs RW, et al. Maternal viral load, zidovudine treatment, and the risk of transmission of human immunodeficiency virus type 1 from mother to infant. N Engl J Med. 1996; 335:1621-1629.
15. Stiehm ER, Lambert JS, Mofenson LM, et al. Efficacy of zidovudine and human immunodeficiency virus (HIV) hyperimmune immunoglobulin for reducing perinatal HIV transmission from HIV-infected women with advanced disease: results of Pediatric AIDS Clinical Trials Group Protocol 185. J Infect Dis. 1999;179:567-575.
16. Ioannidis JP, Abrams EJ, Ammann A, et al. Perinatal transmission of human immunodeficiency virus type 1 by pregnant women with RNA virus loads < 1000 copies/mL. J Infect Dis. 2001;183:539-545.
17. Van Dyke RB, Korber BT, Popek E, et al. The Ariel Project: a prospective cohort study of maternal-child transmission of human immunodeficiency virus type 1 in the era of maternal antiretroviral therapy. J Infect Dis. 1999;179:319-328.
18. Dickover RE, Garratty EM, Herman SA, et al. Identification of levels of maternal HIV-1 RNA associated with risk of perinatal transmission: effect of maternal zidovudine treatment on viral load. JAMA. 1996;275:599-605.
19. Weiser B, Nachman S, Tropper P, et al. Quantitation of human immunodeficiency virus type 1 during pregnancy: relationship of viral titer to mother-to-child transmission and stability of viral load. Proc Natl Acad Sci U S A. 1994;91:8037-8041.
20. Cao Y, Krogstad P, Korber BT, et al. Maternal HIV-1 viral load and vertical transmission of infection: the Ariel Project for the prevention of HIV transmission from mother to infant. Nat Med. 1997;3:549-552.
21. Contopoulos-Ioannidis DG, Ioannidis JP. Maternal cell-free viremia in the natural history of perinatal HIV-1 transmission: a meta-analysis. J Acquir Immune Defic Syndr Hum Retrovirol. 1998;18:126-135.
22. Shaffer N, Roongpisuthipong A, Siriwasin W, et al. Maternal virus load and perinatal human immunodeficiency virus type 1 subtype E transmission, Thailand. Bangkok Collaborative Perinatal HIV Transmission Study Group. J Infect Dis. 1999;179:590-599.
23. Shaffer N, Chuachoowong R, Mock PA, et al. Short-course zidovudine for perinatal HIV-1 transmission in Bangkok, Thailand: a randomized controlled trial. Lancet. 1999;353:773-780.
24. Mofenson LM, Lambert JS, Stiehm, ER, et al. Risk factors for perinatal transmission of human immunodeficiency virus type 1 in women treated with zidovudine. N Engl J Med. 1999;341:385-393.
25. Cooper ER, Charurat M, Mofenson L, et al. Combina tion antiretroviral strategies for the treatment of pregnant HIV-1-infected women and prevention of perinatal HIV 1 transmission. J Acquir Immune Defic Syndr. 2002;29:484-494.
26. Mandelbrot L, Landreau-Mascaro A, Rekacewicz C, et al. Lamivudine-zidovudine combination for prevention of maternal-infant transmission of HIV-1. JAMA. 2001;285:2083-2089.
27. Katzenstein DA, Mbizvo M, Zijenah L, et al. Serum level of maternal human immunodeficiency virus (HIV) RNA, infant mortality, and vertical transmission of HIV in Zimbabwe. J Infect Dis. 1999;179:1382-1387.
28. Chuachoowong R, Shaffer N, Siriwasin W, et al. Short-course antenatal zidovudine reduces both cervicovaginal human immunodeficiency virus type 1 RNA levels and risk of perinatal transmission. Bangkok Collaborative Perinatal HIV Transmission Group. J Infect Dis. 2000;181:99-106.
29. Leroy V, Karon JM, Alioum A, et al. Twenty-four month efficacy of a maternal short-course zidovudine regimen to prevent mother-to-child transmission of HIV-1 in West Africa. AIDS. 2002;16:631-641.
30. Zaman MM, Recco RA, Haag R. Infection with non-B subtype HIV type 1 complicates management of established infection in adult patients and diagnosis of infection in newborn infants. Clin Infect Dis. 2002;34:417-418.
31. Hart CE, Lennox JL, Pratt-Palmore M, et al. Correlation of human immunodeficiency virus type 1 RNA levels in blood and the female genital tract. J Infect Dis. 1999;179:871-882.
32. Shaffer N. Combination prophylaxis for prevention of maternal-infant HIV transmission: beyond 076. JAMA. 2001;285:2129-2131.
33. Aleixo LF, Goodenow MM, Sleasman JW. Zidovudine administered to women infected with human immunodeficiency virus type 1 and to their neonates reduces pediatric infection independent of an effect on levels of maternal virus. J Pediatr. 1997;130:906-914.
34. Owens DK, Holodniy M, McDonald TW, et al. A meta-analytic evaluation of the polymerase chain reaction for the diagnosis of HIV infection in infants. JAMA. 1996;275:1342-1348.
35. Shearer WT, Quinn TC, Larussa P, et al. Viral load and disease progression in infants infected with human immunodeficiency virus type I. N Engl J Med. 1997;336:1337-1342.
36. Cunningham CK, Charbonneau TT, Song K, et al. Comparison of human immunodeficiency virus 1 DNA polymerase chain reaction in human immunodeficiency virus 1-exposed infants. Pediatr Infect Dis J. 1999;18:30-35.
37. Young NL, Shaffer N, Chaowanachan T, et al. Early diagnosis of HIV-1-infected infants in Thailand using RNA and DNA PCR assays sensitive to non-B subtypes. J Acquir Immune Defic Syndr. 2000;24:401-407.
38. Steketee RW, Abrams EJ, Thea DM, et al. Early detection of perinatal human immunodeficiency virus (HIV) type 1 infection using HIV RNA amplification and detection. J Infect Dis. 1997;175:707-711.
39. Reisler RB, Thea DM, Pliner V, et al. Early detection of Reverse Transcriptase activity in plasma of neonates infected with HIV-1: a comparative analysis with RNA-based and DNA-based testing using polymerase chain reaction. J Acquir Immune Defic Syndr. 2001;26:93-102.
40. Simonds RJ, Brown TM, Thea DM, et al. Sensitivity and specificity of a qualitative RNA detection assay to diagnose HIV infection in young infants. AIDS. 1998;12:1545-1549.
41. McIntosh K, Shevitz A, Zaknun D, et al. Age and time-related changes in extracellular viral load in children vertically infected by human immunodeficiency virus. Pediatr Infect Dis J. 1996;15:1087-1091.
42. Dickover RE, Dillon M, Leung KM, et al. Early prognostic indicators in primary human immunodeficiency virus type 1 infection: importance of viral RNA and the timing of transmission on long-term outcome. J Infect Dis. 1998;178:375-387.
43. + lymphocyte count in HIV-infected infants and children. JAMA. 1998;279:756-761.
44. Palumbo PE, Raskino C, Fiscus S, et al. Virologic and immunologic response to nucleoside reverse-transcriptase inhibitor therapy among human immunodeficiency virus-infected infants and children. J Infect Dis. 1999;179:576-583.
45. + cell count, acquired immunodeficiency syndrome, and viral load on disease progression in infants with perinatally acquired human immunodeficiency virus type 1 infection. J Pediatr. 1997;130:890-897.
46. Luzuriaga K, Wu H, McManus M, et al. Dynamics of human immunodeficiency virus type 1 replication in vertically infected infants. J Virol. 1999;73:362-367.
47. Melton AJ, Rodrigo AG, Mohan KM, et al. HIV-1 dynamics in children. J Acquir Immune Defic Syndr Hum Retrovirol. 1999;20:468-473.
48. Perinatal HIV Guidelines Working Group. Public Health Service Task Force Recommendations for use of antiretroviral drugs in pregnant HIV-1 infected women for maternal health and interventions to reduce perinatal HIV-1 transmission in the United States, February 2002. Available at: http://www. aidsinfo.nih.gov/document/data/guidelines_html_lib/perinatal-083002.html. Accessed December 23, 2002.
49. The International Perinatal HIV Group. The mode of delivery and the risk of transmission of human immunodeficiency virus type 1 - a meta-analysis of 15 prospective cohort studies. N Engl J Med. 1999;340:977-987.
50. ACOG committee opinion scheduled cesarean delivery and the prevention of vertical transmission of HIV infection. Number 234, May 2000. Int J Gynaecol Obstet. 2001;73:279-281.